Company news

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A (SSE:600267) news

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 28, 2026: "Zhejiang Hisun Pharmaceutical Co., Ltd."Indicative Announcement…

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A (SSE:600267) news

Press releases & updates

"Zhejiang Hisun Pharmaceutical Co., Ltd."Indicative Announcement on Results of the Agreement-based Transfer of the Company's Shares by Shareholder Holding More Than 5% of the Shares through Public Solicitation and Signing of the Share Transfer Agreement with the Transferee

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval for Veterinary Drug Product Approval Number by a Subsidiary

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Company's Product Passing the U.S. Self-GRAS Certification

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Obtaining New Veterinary Drug Registration Certificate by Subsidiary

"Zhejiang Hisun Pharmaceutical Co., Ltd."Indicative Announcement on Convening the 3rd Extraordinary General Meeting in 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Change of Board Secretary

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Obtainment of CEP Certificate for Epirubicin Hydrochloride Active Pharmaceutical Ingredient

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Release of Overdue Guarantee for an Investee Subsidiary

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Company's Proposed Selection in the National Centralized Drug Procurement

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned Subsidiary

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Expected Increase in Semi-annual Performance for 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Signing of an Exclusive Product Licensing and Cooperation Agreement

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary

Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Letermovir API

Announcement on Implementation of the 2nd Share Repurchase Cancellation and Share Capital Changes

Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Finerenone API

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Obtaining Drug Registration Certificate

Announcement on Outline of Reception Day for Investors

Announcement on Resolutions of the 2025 Annual General Meeting

Report for Q1 2026

Indicative Announcement on Convening the 2025 Annual General Meeting

Announcement on Preliminary Earnings Estimate for Q1 2026

Announcement on Estimated Daily Related Party Transactions in 2026

Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug

Announcement on Implementation Results of the 4th Share Repurchase and Share Changes

Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials

Correction Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right

Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right

Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary

Announcement on the Obtainment of CEP Certificate for Ticagrelor Active Pharmaceutical Ingredient

Announcement on Lifting Trading Restrictions in the 3rd Trade Restriction Release Period for Reserved Granted Parts under 2021 Restricted Stock Incentive Plan and Stock Marketing

Announcement on Progress in Capital Increase and Debt-to-Share Swap Matters of Zhejiang Dtrm BioPharma Co., Ltd.

Announcement on Progress in Repurchasing Shares through Call Auction for the 4th Time

Announcement on Approval by the US FDA of the Formulation Product Micafungin Sodium for Injection of the Wholly-owned Subsidiary

Announcement on Receiving Warning Letter from Zhejiang Office of China Securities Regulatory Commission

Announcement on Resolutions of the 12th Meeting of the 10th Board of Directors

Announcement on the Listing Application Submitted by the Joint-stock Subsidiary to the Hong Kong Stock Exchange

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Indicative Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Obtaining the Notice on Approval of Drug Supplement Application

Announcement on HS387 Tablets Obtaining the U.S. FDA Approval for Clinical Trials of a New Drug

Announcement on the Subsidiary Obtaining New Veterinary Drug Registration Certificate